Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Overview
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development
Eli Lilly and Co
NeurAxon Pharma Inc
Neurophyxia BV
SalubRx Therapeutics Inc
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles
2-Iminobiotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-462 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-613 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Products
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neurol NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by NeurAxon Pharma Inc, H1 2020
Pipeline by Neurophyxia BV, H1 2020
Pipeline by SalubRx Therapeutics Inc, H1 2020
Dormant Projects, H1 2020